{"filing":{"accession_number":"0001193125-26-303393","cik":"0002093101","ticker":"RNA","company_name":"Atrium Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"d132402d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526303393/d132402d8k.htm"},"events":[{"id":17936,"run_id":16089,"accession_number":"0001193125-26-303393","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The disclosure announces FDA clearance of an IND application for ATR 1072, enabling the company to initiate its Corventis™ Phase 1/2 clinical trial for PRKAG2 syndrome. This is a material regulatory milestone for a biopharmaceutical company's lead precision cardiology program, representing significant progress in clinical development. While not a specific named event type, this is clearly an operational/strategic milestone—the advancement of a key product candidate into human clinical trials—that would affect a reasonable investor's assessment of the company's pipeline and near-term prospects.","company_name":"Atrium Therapeutics, Inc.","ticker":"RNA","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16596,"accession_number":"0001193125-26-303393","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces FDA clearance of an IND application for ATR 1072, enabling the company to initiate its Corventis™ Phase 1/2 clinical trial for PRKAG2 syndrome. This is a material regulatory milestone for a biopharmaceutical company's lead precision cardiology program, representing significant progress in clinical development. While not a specific named event type, this is clearly an operational/strategic milestone—the advancement of a key product candidate into human clinical trials—that would affect a reasonable investor's assessment of the company's pipeline and near-term prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T21:15:38.250820+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16596,"accession_number":"0001193125-26-303393","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces FDA clearance of an IND application for ATR 1072, enabling the company to initiate its Corventis™ Phase 1/2 clinical trial for PRKAG2 syndrome. This is a material regulatory milestone for a biopharmaceutical company's lead precision cardiology program, representing significant progress in clinical development. While not a specific named event type, this is clearly an operational/strategic milestone—the advancement of a key product candidate into human clinical trials—that would affect a reasonable investor's assessment of the company's pipeline and near-term prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T21:15:38.250820+00:00","company_name":"Atrium Therapeutics, Inc.","ticker":"RNA","filing_date":"2026-07-14"}]}